Product Information
OXYTROL FOR WOMEN 3.9 MG/24HR is a brand product labeled by Allergan, Inc., priced at $2.7424 per EA under NDC 00023963704. Its NADAC has been published 356 times since Dec 11, 2019.
FDA first approved this application on Jan 25, 2013.
Strength
3.9 mg/d
Manufacturer
Allergan, Inc.NDC
00023963704
Classification
Brand
Dosage Form
PATCH
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNINApproval Type
New Drug (NDA)
FDA Application
NDA202211FDA Approved
1/25/2013
On Market Since
1/1/2016
Pharmacological Classes
Price Statistics
The NADAC for OXYTROL FOR WOMEN 3.9 MG/24HR has been published 356 times since Dec 11, 2019, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7424 per EA |
|---|---|
| All-time high | $2.7788 (Oct 14, 2020) |
| All-time low | $2.5680 (Oct 20, 2021) |
| 52-week high | $2.7497 |
| 52-week low | $2.7140 |
| Median price | $2.7140 |
| Average price | $2.6974 |
| Largest weekly change | -6.0% (Oct 20, 2021) |
| Weeks tracked | 356 |
| Tracking since | Dec 11, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxybutynin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYTROL FOR WOMEN 3.9 MG/24HR?
The current National Average Drug Acquisition Cost (NADAC) for OXYTROL FOR WOMEN 3.9 MG/24HR, manufactured by Allergan, Inc., is $2.7424 per EA (NDC 00023963704), effective Sep 30, 2026.
How has the price of OXYTROL FOR WOMEN 3.9 MG/24HR changed over time?
Over the history we have for it, the NADAC for OXYTROL FOR WOMEN 3.9 MG/24HR has held within roughly two percent of its current level. It has been tracked across 356 weekly CMS publications since Dec 11, 2019.
What are the highest and lowest recorded NADAC prices for OXYTROL FOR WOMEN 3.9 MG/24HR?
Since Dec 11, 2019, the NADAC for OXYTROL FOR WOMEN 3.9 MG/24HR has ranged from a low of $2.5680 (Oct 20, 2021) to a high of $2.7788 (Oct 14, 2020), with a median of $2.7140 per EA.
Are there cheaper alternatives to OXYTROL FOR WOMEN 3.9 MG/24HR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as OXYTROL FOR WOMEN 3.9 MG/24HR in a comparable dosage form, but none are currently priced below it.
Who manufactures OXYTROL FOR WOMEN 3.9 MG/24HR?
OXYTROL FOR WOMEN 3.9 MG/24HR (NDC 00023963704) is labeled by Allergan, Inc., and CMS classifies it as a brand product.